ACTIVATION MARKERS ON T-CELLS INFILTRATING MELANOMA METASTASES AFTER THERAPY WITH DINITROPHENYL-CONJUGATED VACCINE

被引:37
作者
BERD, D [1 ]
MAGUIRE, HC [1 ]
MASTRANGELO, MJ [1 ]
MURPHY, G [1 ]
机构
[1] UNIV PENN,SCH MED,DEPT DERMATOL,PHILADELPHIA,PA 19104
关键词
MELANOMA; VACCINE; HAPTEN; TIL; T CELL ACTIVATION;
D O I
10.1007/BF01533378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Treatment of metastatic melanoma patients with an autologous vaccine modified by the hapten, dinitrophenyl (DNP), produces a striking immunological effect:the induction of clinically evident inflammatory responses in metastatic tumors. Histological examination shows these tumors to be infiltrated with T lymphocytes. We studied the expression of activation markers on those cells and compared them with matched peripheral blood lymphocytes (PBL) and with lymphocytes extracted from metastases before treatment with DNP-conjugated vaccine. The median fraction of cells that were T cells in post-vaccine tumors was 41%, as compared with 9% in pre-treatment tumors, and those T cells were predominantlyCD8+ (mean CD8/CD4 ratio = 5.0). A high proportion of both pre- and post-treatment infiltrating t cells expressed HLA-DR (mean +/- SE = 48% +/- 4%), CD69 (56% +/- 7%), and ganglioside GD3 (68% +/- 5%). This distinguished them from matched PBL in which expression of those markers was significantly lower (HLA-DR+ 10% +/- 2%; CD69 + 2% +/- 0.4%; GD3 = 49% +/- 4%). These changes were not accompanied by increase cell-surface expression of interleukin-2 (IL-2) receptors, either CD25 or p75, which were expressed by 1%-2% and 12% of tumor-infiltrating lymphocytes (TIL), respectively. The pattern of activation marker expression that we identified appears to be characteristic of tissue T cells with the memory phenotype. The low expression of IL-2 receptors could indicate functional impairment of TIL in situ, perhaps because of inhibitory molecules produced by melanoma cells.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 22 条
[1]  
ALEXANDER JP, 1993, CANCER RES, V53, P1380
[2]   CLONAL ANALYSIS OF THE CYTOLYTIC T-CELL RESPONSE TO HUMAN-TUMORS [J].
ANICHINI, A ;
FOSSATI, G ;
PARMIANI, G .
IMMUNOLOGY TODAY, 1987, 8 (12) :385-389
[3]  
BERD D, 1993, ANN NY ACAD SCI, V690, P147
[4]  
BERD D, 1986, CANCER RES, V46, P2572
[5]  
BERD D, 1991, CANCER RES, V51, P2731
[6]   TRANSIENT EXPRESSION OF INTERLEUKIN-2 RECEPTORS - CONSEQUENCES FOR T-CELL GROWTH [J].
CANTRELL, DA ;
SMITH, KA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1983, 158 (06) :1895-1911
[7]  
CARDI G, 1989, CANCER RES, V49, P6562
[8]  
COHEN PJ, 1987, AM J PATHOL, V129, P208
[9]   SIMULTANEOUS FLOW CYTOMETRIC ANALYSIS OF HUMAN T-CELL ACTIVATION ANTIGEN EXPRESSION AND DNA CONTENT [J].
COTNER, T ;
WILLIAMS, JM ;
CHRISTENSON, L ;
SHAPIRO, HM ;
STROM, TB ;
STROMINGER, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1983, 157 (02) :461-472
[10]  
ELDER DE, 1979, HUMAN MALIGNANT MELA, P100